developed a cyclic peptide named C25, which shows a significant anti-tumor effect in CT26 (colorectal cancer), B16, and B16-OVA (melanoma) mouse tumor models by inhibiting the interaction between LAG3 and MHC-II, as well as the increased CD8+ T cell and decreased Treg cell levels. This evidence concerns the gene CD8A and neoplasm.